Key result
Alpha-interferon initiation without immunosuppression worsened polyneuropathy, and prednisone deteriorated liver function despite improving polyneuropathy in two patients with HCV cryoglobulinemia.
Why the study?
What are the treatment outcomes of alpha-interferon and prednisone in patients with mononeuropathy multiplex in hepatitis C virus-associated cryoglobulinemia?
Case Report (n=2)
What are the treatment outcomes of alpha-interferon and prednisone in patients with mononeuropathy multiplex in hepatitis C virus-associated cryoglobulinemia?
Treatment of HCV-associated cryoglobulinemic mononeuropathy multiplex with alpha-interferon or prednisone can lead to significant adverse outcomes, highlighting the need for careful management.
May worsen neuropathy or liver function with alpha-interferon or prednisone in HCV cryoglobulinemia; leaves open optimal regimens for mononeuropathy multiplex.
Recent reports advocate alpha-interferon (alpha-Ifn) treatment for mononeuropathy multiplex in hepatitis C virus-associated cryoglobulinemia. We report 2 patients with this disorder to describe two underrecognized treatment outcomes--worsening of polyneuropathy with initiation of alpha-Ifn, in the absence of immunosuppression, and deterioration of liver function with prednisone, despite improvement of polyneuropathy.
No takes yet. Share an insight, caveat, or question.
Scelsa et al. (1998) conducted a case report in mononeuropathy multiplex in hepatitis C virus-associated cryoglobulinemia (n=2). alpha-interferon and prednisone was evaluated on treatment outcomes (polyneuropathy and liver function). Alpha-interferon initiation without immunosuppression worsened polyneuropathy, and prednisone deteriorated liver function despite improving polyneuropathy in two patients with HCV cryoglobulinemia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: